Core B: Clinical Core

核心 B：临床核心

• 批准号: 9280777
• 负责人: JAMES J LAH
• 金额: $ 39.33万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-06-01 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9280777
• 关键词: Abeta clearance; Address; Affect; African American; Alzheimer disease prevention; Alzheimer' s Disease; American; Amyloid beta-Protein; Area; Autopsy; Basic Science; Biological; Biological Markers; Blood; Blood specimen; Brain; Cerebrospinal Fluid; Clinical; Clinical Data; Clinical Research; Clinical Trials; Cognition; Cognitive; Cognitive aging; Collection; Communities; Cross-Sectional Studies; Data; Data Quality; Dementia; Diagnosis; Disease; Disease Progression; Education; Elderly; Elements; Enrollment; Evolution; Failure; Funding; Genetic; Genotype; Goals; Hispanic Americans; Impaired cognition; Individual; International; Magnetic Resonance Imaging; Memory Loss; Multicenter Studies; Nerve Degeneration; Neurodegenerative Disorders; Onset of illness; Participant; Pathologic; Pathology; Patients; Pharmaceutical Preparations; Play; Population; Positioning Attribute; Process; Production; Public Health; Recruitment Activity; Research; Research Personnel; Research Support; Resources; Risk; Role; Sampling; Specimen; Symptoms; Therapeutic; United States National Institutes of Health; Work; base; cohort; combat; data management; drug testing; effective therapy; enhancing factor; improved; innovation; mild cognitive impairment; neuroimaging; neuropathology; outreach; peptide drug; pre-clinical; success; volunteer

SUMMARY/ABSTRACT: CLINICAL CORE (CORE B) The primary goals of the Emory ADRC Clinical Core are to support and enhance research efforts to understand the causes of Alzheimer's disease and related neurodegenerative disorders in order to develop effective treatments. To accomplish these goals, the Clinical Core maintains a cohort of volunteers who allow investigators to examine the process of normal and pathological cognitive aging, provide essential biological specimens and neuroimaging data, and serve as participants in promising clinical trials. The Clinical Core contributes to local, national, and international studies and reflects NIA-defined network-wide priorities. In the current funding period, the Core has provided top-quality clinical data and biological samples to national coordinating centers, and has maximized community engagement and participation of African-American older adults in ADRC-sponsored research and related projects. Specific Aims for this renewal are to 1) continue to maintain a cohort of well-characterized participants to support efforts to understand normal cognitive aging and decline due to AD and related disorders; 2) develop innovative approaches to increase the participation of African Americans in AD research; and 3) establish a Longitudinal Biomarker Collection to support research and improve understanding of the early stages of pathological cognitive aging. We will focus our efforts on preclinical disease and mild cognitive impairment since treatments are more likely to be successful if implemented at an early stage. We also plan to double the current cohort to include 50% African Americans to address stark racial imbalances in understanding clinical, pathological, and genetic features of AD and to make data available for multicenter studies. As part of this effort, we will collect data to define elements that improve success in recruiting and engaging African-American research volunteers. Longitudinal biomarker sampling of blood, CSF, and neuroimaging will provide a powerful resource since cross-sectional studies limit our ability to identify predictors of AD onset and progression. The themes and goals that are proposed for the Clinical Core are consistent with the overall focus of the Emory ADRC, and it will serve as a powerful proponent for basic and clinical research efforts to advance our abilities to diagnose and treat patients suffering from AD and other neurodegenerative dementing diseases.

总结/摘要：临床核心（核心B） 埃默里ADRC临床核心的主要目标是支持和加强研究工作， 了解阿尔茨海默病和相关神经退行性疾病的原因，以便开发 有效的治疗。为了实现这些目标，临床核心维持了一批志愿者，他们允许 研究人员研究正常和病理性认知老化的过程，提供必要的生物学 标本和神经影像学数据，并作为有前途的临床试验的参与者。临床核心 有助于地方，国家和国际研究，并反映NIA定义的网络范围内的优先事项。在 在目前的资助期间，核心为国家提供了高质量的临床数据和生物样本， 协调中心，并最大限度地提高了社区参与和非洲裔美国老年人的参与 成人在ADRC赞助的研究和相关项目。 本次更新的具体目标是：1）继续保持一个特征良好的参与者队列， 支持理解正常认知老化和AD及相关疾病所致认知能力下降的努力; 2）开发 创新的方法，以增加非裔美国人在AD研究的参与;和3）建立一个 纵向生物标志物收集，以支持研究和提高对早期阶段的理解， 病理性认知老化我们将集中精力于临床前疾病和轻度认知障碍 因为如果在早期阶段实施治疗更有可能成功。我们还计划将 目前的队列包括50%的非洲裔美国人，以解决在理解临床， AD的病理学和遗传学特征，并为多中心研究提供数据。作为其中的一部分 努力，我们将收集数据，以确定提高招聘和吸引非洲裔美国人的成功要素 研究志愿者血液、CSF和神经影像学的纵向生物标志物采样将提供强有力的 因为横断面研究限制了我们识别AD发病和进展预测因子的能力。的 为临床核心提出的主题和目标与埃默里大学的总体重点一致 ADRC，它将作为基础和临床研究工作的有力支持者，以提高我们的能力 诊断和治疗患有AD和其他神经退行性痴呆疾病的患者。